Histone deacetylase inhibitors are potent radiation protectants

Luca Paoluzzi, William D. Figg

Research output: Contribution to journalShort survey

13 Citations (Scopus)

Abstract

Radiation-induced acute and late injuries often represent a limit to the optimal delivery of radiotherapy in cancer patients. Chung et al. reported that histone deacetylase (HDAC) inhibitors, a novel class compound of gene modulators, might have a role in controlling different adverse effects from radiotherapy in preclinical models. They also showed how protection of normal tissues and inhibition of tumor growth might be possible at the same time.

Original languageEnglish (US)
Pages (from-to)612-613
Number of pages2
JournalCancer Biology and Therapy
Volume3
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Radiation-Protective Agents
Histone Deacetylase Inhibitors
Radiotherapy
Neoplasms
Radiation
Wounds and Injuries
Growth
Genes

Keywords

  • Cutaneous radiation syndrome
  • Histone deacetylase inhibitors
  • Phenylbutyrate
  • Radiotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Histone deacetylase inhibitors are potent radiation protectants. / Paoluzzi, Luca; Figg, William D.

In: Cancer Biology and Therapy, Vol. 3, No. 7, 07.2004, p. 612-613.

Research output: Contribution to journalShort survey

@article{2510e175051a4e4b843250848ad6da9f,
title = "Histone deacetylase inhibitors are potent radiation protectants",
abstract = "Radiation-induced acute and late injuries often represent a limit to the optimal delivery of radiotherapy in cancer patients. Chung et al. reported that histone deacetylase (HDAC) inhibitors, a novel class compound of gene modulators, might have a role in controlling different adverse effects from radiotherapy in preclinical models. They also showed how protection of normal tissues and inhibition of tumor growth might be possible at the same time.",
keywords = "Cutaneous radiation syndrome, Histone deacetylase inhibitors, Phenylbutyrate, Radiotherapy",
author = "Luca Paoluzzi and Figg, {William D.}",
year = "2004",
month = "7",
doi = "10.4161/cbt.3.7.931",
language = "English (US)",
volume = "3",
pages = "612--613",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "7",

}

TY - JOUR

T1 - Histone deacetylase inhibitors are potent radiation protectants

AU - Paoluzzi, Luca

AU - Figg, William D.

PY - 2004/7

Y1 - 2004/7

N2 - Radiation-induced acute and late injuries often represent a limit to the optimal delivery of radiotherapy in cancer patients. Chung et al. reported that histone deacetylase (HDAC) inhibitors, a novel class compound of gene modulators, might have a role in controlling different adverse effects from radiotherapy in preclinical models. They also showed how protection of normal tissues and inhibition of tumor growth might be possible at the same time.

AB - Radiation-induced acute and late injuries often represent a limit to the optimal delivery of radiotherapy in cancer patients. Chung et al. reported that histone deacetylase (HDAC) inhibitors, a novel class compound of gene modulators, might have a role in controlling different adverse effects from radiotherapy in preclinical models. They also showed how protection of normal tissues and inhibition of tumor growth might be possible at the same time.

KW - Cutaneous radiation syndrome

KW - Histone deacetylase inhibitors

KW - Phenylbutyrate

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=16644389497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16644389497&partnerID=8YFLogxK

U2 - 10.4161/cbt.3.7.931

DO - 10.4161/cbt.3.7.931

M3 - Short survey

C2 - 15136769

AN - SCOPUS:16644389497

VL - 3

SP - 612

EP - 613

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 7

ER -